News and Trends 5 Dec 2022
Faron Pharmaceuticals provides cancer treatment update
Faron Pharmaceuticals Oy has given an update on its phase I/II BEXMAB study, investigating bexmarilimab. Bexmarilimab is Faron’s wholly owned precision immunotherapy asset, in combination with standard of care (SoC)…
